MediWound launches mid-stage study of EscharEx in venous leg ulcers

MediWound (MDWD -1.2%) initiates a Phase 2 clinical trial evaluating EscharEx, a topical biologic designed to enzymatically debride (remove dead tissue) chronic wounds, for the treatment of venous leg ulcers.

The primary endpoint is the incidence of complete debridement within two weeks (up to eight applications of EscharEx).

Preliminary data should be available in about a year.

https://seekingalpha.com/news/3523400-mediwound-launches-mid-stage-study-of-escharex-in-venous-leg-ulcers